...how many patients will use Tysabri?
: "In the case of Elan (ELN, now that the Food and Drug Administration has re-approved its multiple sclerosis drug, Tysabri, the issue is: how many patients will use Tysabri?

Our community-based research has shown that for most multiple-sclerosis patients, the current drugs (all of them blockbusters) have undesirable side effects or just don't work. Tysabri has had such miraculous results that MS patients are willing to give up all other drugs to be first in line to receive treatments when Tysabri returns to the market in July.

Our research convinces me that Tysabri will be a multibillion-dollar drug -- and interest rates, the price of oil, and the election will not affect an MS patient's decision to use Tysabri. So when Wall Street panics, as it did in January when ELN dropped 22% in two days or in June when ELN dropped 24% in two days, that's the time to buy a stock that can double over the next couple of years...."